Prognostic implications of glucose transporter protein-1 (Glut-1) overexpression in bone and soft-tissue sarcomas

Japanese Journal of Clinical Oncology

Volumn 37, Issue 12, 2007, Pages 955-960

  Endo, Makoto ^a   Tateishi, Ukihide ^a   Seki, Kunihiko ^a   Yamaguchi, Umio ^a   Nakatani, Fumihiko ^a   Kawai, Akira ^a   Chuman, Hirokazu ^a   Beppu, Yasuo ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Glucose trasnsporter protein; Prognosis; Sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHONDROSARCOMA; CLINICAL FEATURE; EPITHELIOID SARCOMA; EWING SARCOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS INDEX; MYXOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR NECROSIS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SARCOMA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 38749108156     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym125     Document Type: Article

References (20)

1. Hasegawa T, Yamamoto S, Yokoyama, R, Umeda T, Matsuno Y, Hirohashi S. Prognostic significance of grading and staging system using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 2002;95:843-51.
2. Kulander BG, Polissar L, Yang CY, Woods JS. Grading of soft tissue sarcomas: Necrosis as a determinant of survival. Mod Patho. 1989;2:205-8
3. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56: 4509-15.
4. Airley RE, Phillips RM, Evans AE, Double J, Burger AM, Feibig HH., et al. Hypoxia-rcgulated glucose transporter Glut-1 may influence the mosensitivity to some alkylating agents: Results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol 2005;26:1477-94.
5. Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM. Is the hypoxia-inducible factor pathway important in gastric cancer? Eur J Cancer 2005;41:2792-805.
6. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001;28:36-41.
7. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003;97:1015-24.
8. Kato H, Takita J, Miyazaki T, Nakajima M, Fukai Y, Masuda N, et al. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 2003;23:3263-72.
9. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164-7.
10. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-five survival in advanced carcinoma of the cervix. Clin Cancer Res 2001;7:928-34.
11. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. Int J Cancer 2003;104:85-91.
12. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glutl and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51.
13. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma: A marker for poor prognosis. Cancer 1998;83:34-40.
14. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al. GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. Cancer 2001;92:1144-50.
15. Green FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 6th edn. Now York: Springer 2002.
16. Sobin LH, Wittekind C. UICC TNM Classification of Malignant Tumours. 6th edn. New York: Wiley 2002.
17. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press 2002.
18. Hasegawa T, Yamamoto S, Nojima T, Hirose T, Nikaido T, Yamashiro K, et al. Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol 2002;33:111-5.
19. Haberkorn U, Bellemann ME, Brix G, Kamencic H, Morr I, Traut U, et al. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med 2001;28:418-25.
20. Medina RA, Owen GI. Glucose transporters: Expression, regulation and cancer. Biol Res 2002;35:9-26.